Edwards Lifesciences (NYSE:EW) Sets New 1-Year High – Should You Buy?

Edwards Lifesciences Corporation (NYSE:EW)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $94.60 and last traded at $93.1050, with a volume of 222940 shares trading hands. The stock had previously closed at $94.37.

Analyst Ratings Changes

Several analysts recently issued reports on EW shares. TD Cowen reissued a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. Barclays restated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $96.39.

Edwards Lifesciences Stock Performance

The stock has a market cap of $53.94 billion, a price-to-earnings ratio of 49.82, a PEG ratio of 2.37 and a beta of 0.86. The company’s 50 day simple moving average is $85.61 and its 200 day simple moving average is $83.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 57,958 shares of company stock valued at $4,839,284. Company insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the first quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter worth approximately $25,000. MV Capital Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter worth approximately $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the first quarter valued at $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at $27,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.